| Literature DB >> 34281000 |
Lionel Larribère1, Jelizaveta Gordejeva2, Lisa Kuhnhenn3, Maximilian Kurscheidt2, Monika Pobiruchin2, Dilyana Vladimirova1, Maria Martin4, Markus Roser3, Wendelin Schramm2, Uwe M Martens1, Tatjana Eigenbrod3.
Abstract
To date, more than 160 million people have been infected with COVID-19 worldwide. In the present study, we investigated the history of SARS-CoV-2 infection among 3067 healthcare workers (HCW) in a German COVID-19 treatment center during the early phase of the pandemic (July 2020) based on the seroprevalence of SARS-CoV-2 antibodies and self-reported previous PCR results. The results demonstrate a low prevalence of SARS-CoV-2 infection (n = 107 [3.5%]) with no increased risk for employees with a high level of patient exposure in general or working in COVID-19-confined areas in particular. This suggests that the local hygiene standards implemented in our hospital during the first wave of COVID-19 pandemic were effective in preventing patient-to-HCW transmission. No evidence for highly mobile staff serving as a vector for SARS-CoV-2 transmission could be found. In addition, impairment of smell and/or taste was strongly associated with SARS-CoV-2 history.Entities:
Keywords: COVID-19; SARS-CoV-2; epidemiology; health care workers; infection risk; infectious disease; transmission
Mesh:
Year: 2021 PMID: 34281000 PMCID: PMC8297119 DOI: 10.3390/ijerph18137057
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Distribution of previous SARS-CoV-2 PCR tests and serostatus. (a) Venn diagram represents 107 cases with SARS-CoV-2 history. (b) Table depicts the distribution of PCR tests in the whole cohort (n = 3067).
Association between history of SARS-CoV-2 infection and sociodemographic or working characteristics. CI: confidence interval; OR: odds ratio; Significance codes (SC): ≤0.001—***/≤0.01—**/≤0.05—*; Intercept: OR [95% CI] = 0.02 [0.00;0.12], p-Value = 0.00045.
| Negative n (%) # | Positive n (%) # | OR [95% CI] | SC | ||
|---|---|---|---|---|---|
|
| |||||
| 14–19 (Ref. Group) | 48 (1.6) | 1 (0.9) | |||
| 20–29 | 515 (17.4) | 19 (17.8) | 1.87 [0.36;34.29] | 0.55090 | |
| 30–39 | 660 (22.3) | 27 (25.2) | 2.12 [0.42;38.77] | 0.47152 | |
| 40–49 | 627 (21.2) | 21 (19.6) | 1.81 [0.36;33.20] | 0.56863 | |
| 50–59 | 830 (28.1) | 32 (29.9) | 2.26 [0.45;41.07] | 0.43346 | |
| ≥60 | 279 (9.4) | 7 (6.5) | 1.38 [0.23;26.47] | 0.76833 | |
|
| |||||
| Female (Ref. Group) | 2377 (80.3) | 76 (71.0) | |||
| Male | 562 (19.0) | 31 (29.0) | 1.77 [1.05;2.92] | 0.02735 | * |
| Not specified | 20 (0.7) | - | 0.00 [-] | 0.99133 | |
|
| |||||
| No (Ref. Group) | 2753 (93.0) | 95 (88.8) | |||
| Yes | 168 (5.7) | 9 (8.4) | 1.67 [0.75;3.29] | 0.16849 | |
| Not specified | 38 (1.3) | 3 (2.8) | 2.86 [0.65;8.77] | 0.10124 | |
|
| |||||
| <10% (Ref. Group) | 1297 (43.8) | 48 (44.9) | |||
| 10–50% | 294 (9.9) | 4 (3.7) | 0.73 [0.44;1.20] | 0.22103 | |
| >50% | 1958 (66.2) | 82 (76.6) | 1.00 [0.59;1.65] | 0.98574 | |
| Not specified | 40 (1.4) | - | 1.57 [0.24;5.69] | 0.55710 | |
|
| |||||
| <10% (Ref. Group) | 667 (22.5) | 21 (19.6) | |||
| 10–50% | 294 (9.9) | 4 (3.7) | 0.37 [0.10;1.11] | 0.10087 | |
| >50% | 1958 (66.2) | 82 (76.6) | 1.08 [0.47;2.65] | 0.85662 | |
| Not specified | 40 (1.4) | - | 0.00 [-] | 0.98755 | |
|
| |||||
| Physicians (Ref. Group) | 445 (15.0) | 17 (15.9) | |||
| Administration, patient management, reception | 356 (12.0) | 10 (9.3) | 0.81 [0.27;2.38] | 0.69788 | |
| Housekeeping and transport services | 186 (6.3) | 1 (0.9) | 0.17 [0.01;0.90] | 0.09369 | |
| IT and technical services | 73 (2.5) | 9 (8.4) | 3.10 [0.98;9.68] | 0.05174 | |
| Laboratory, pathology and pharmacy staff | 111 (3.8) | - | 0.00 [-] | 0.98017 | |
| Nursing staff, medical assistance and non-medical therapists | 1629 (55.1) | 69 (64.5) | 1.35 [0.74;2.57] | 0.33705 | |
| Others/not specified | 159 (5.4) | 1 (0.9) | 0.21 [0.01;1.16] | 0.14371 | |
|
| |||||
| No (Ref. Group) | 1818 (61.4) | 67 (62.6) | |||
| Yes, COVID-19 suspect ward | 260 (8.8) | 12 (11.2) | 1.08 [0.54;2.00] | 0.80862 | |
| Yes, combinations of COVID-19 wards and ER | 353 (11.9) | 11 (10.3) | 0.66 [0.32;1.26] | 0.23625 | |
| Yes, COVID-19 ICU | 215 (7.3) | 5 (4.7) | 0.46 [0.16;1.08] | 0.10652 | |
| Yes, COVID-19 ward | 102 (3.4) | 2 (1.9) | 0.47 [0.08;1.55] | 0.29777 | |
| Yes, ER | 165 (5.6) | 10 (9.3) | 1.38 [0.64;2.73] | 0.37505 | |
| Not specified | 46 (1.6) | - | 0.00 [-] | 0.98642 | |
# Analysis was performed on a total of participants n = 3066 (1 exclusion due to an implausible answer given in the questionnaire).
History of SARS-CoV-2 infection in participants and association with COVID-19 associated clinical symptoms. CI: confidence interval; OR: odds ratio; Significance codes (SC): ≤0.001—***/≤0.01—**/≤0.05—*; Intercept: OR [95% CI] = 0.05 [0.04;0.06], p-Value = 0.00000.
| Negative n (%) | Positive n (%) | OR [95% CI] | SC | ||
|---|---|---|---|---|---|
| Headache (Ref.Group) | 1298 (43.9) | 65 (60.7) | |||
| Fever ≥ 38 °C | 338 (11.4) | 51 (47.7) | 3.01 [2.04; 4.42] | 0.00000 | *** |
| Impairment of taste/smell | 100 (3.4) | 56 (52.3) | 11.18 [7.41; 16.89] | 0.00000 | *** |
| Congested/running nose | 1161 (39.2) | 51 (47.7) | 0.88 [0.60; 1.27] | 0.49358 | |
| Cough | 958 (32.4) | 52 (48.6) | 1.08 [0.74; 1.57] | 0.67286 | |
| Sore throat/hoarseness | 1204 (40.7) | 47 (43.9) | 0.78 [0.53; 1.14] | 0.20292 | |
| Shortness of breath | 296 (10.0) | 35 (32.7) | 2.36 [1.52; 3.61] | 0.00009 | *** |
| Respiratory distress | 88 (3.0) | 11 (10.3) | 2.50 [1.21; 4.72] | 0.00786 | ** |
| Abnormal sleepiness/drowsiness | 64 (2.2) | 10 (9.3) | 3.12 [1.45; 6.11] | 0.00172 | ** |
| Apathy | 31 (1.0) | 11 (10.3) | 7.09 [3.28; 14.35] | 0.00000 | *** |
| Loss of appetite | 130 (4.4) | 27 (25.2) | 4.15 [2.52; 6.66] | 0.00000 | *** |
| Weight loss | 53 (1.8) | 13 (12.1) | 4.90 [2.45; 9.20] | 0.00000 | *** |
| Stomach pain | 291 (9.8) | 6 (5.6) | 0.41 [0.16; 0.88] | 0.03977 | * |
| Diarrhea | 453 (15.3) | 19 (17.8) | 0.84 [0.48; 1.38] | 0.50587 | |
| Nausea/vomit | 230 (7.8) | 11 (10.3) | 0.96 [0.47; 1.76] | 0.89041 | |
| Joint pain | 508 (17.2) | 37 (34.6) | 1.45 [0.95; 2.19] | 0.07789 | |
| Muscle pain | 459 (15.5) | 40 (37.4) | 1.74 [1.15; 2.61] | 0.00778 | ** |
| Swollen lymph nodes | 135 (4.6) | 6 (5.6) | 0.89 [0.34; 1.93] | 0.78441 | |
| Conjunctivitis | 76 (2.6) | 7 (6.5) | 1.84 [0.75; 3.89] | 0.14194 | |
| Skin rash | 106 (3.6) | 7 (6.5) | 1.32 [0.54; 2.76] | 0.50025 | |
| Malaise/weakness | 634 (21.4) | 61 (57.0) | 1.92 [1.34; 2.76] | 0.00041 | *** |
| Other symptoms | 51 (1.7) | 9 (8.4) | 3.52 [1.57; 7.15] | 0.00101 | ** |
| No symptoms since 1 January 2020 | 734 (24.8) | 5 (4.7) | 0.14 [0.05; 0.31] | 0.00002 | *** |
| Not specified | 111 (3.8) | 2 (1.9) | 0.36 [0.06; 1.17] | 0.15838 |